Evidence map›Paper›PMID 42578958›Full record

ArticleThe Journal of cell biology2026

EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery.

Sergi Marco, Peter J Walsh, Alexey S Revenko, Tobias Schmidt, Peter A Thomason, Lynn McGarry, A Robert MacLeod, Sonam Ansel, Dina Tataran, Martin Bushell and 2 more

Abstract read
In one paragraph

Article in The Journal of cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sergi MarcoCancer Research UK Scotland Institute , Glasgow, UK.ORCID 0000-0002-9747-0388
Peter J WalshCancer Research UK Scotland Institute , Glasgow, UK.ORCID 0009-0004-6980-9251
Alexey S RevenkoIonis Pharmaceuticals Inc. , Carlsbad, CA, USA.ORCID 0000-0002-4863-362X
Tobias SchmidtCancer Research UK Scotland Institute , Glasgow, UK.ORCID 0000-0001-7230-1214
Peter A ThomasonCancer Research UK Scotland Institute , Glasgow, UK.ORCID 0000-0003-3104-8392
Lynn McGarryCancer Research UK Scotland Institute , Glasgow, UK.ORCID 0000-0002-7055-2615
A Robert MacLeodIonis Pharmaceuticals Inc. , Carlsbad, CA, USA.ORCID 0009-0002-9381-7927
Sonam AnselCancer Research UK Scotland Institute , Glasgow, UK.ORCID 0000-0003-0154-5603
Dina TataranSchool of Cancer Sciences, University of Glasgow , Glasgow, UK.ORCID 0009-0001-2404-2032
Martin BushellCancer Research UK Scotland Institute , Glasgow, UK.ORCID 0000-0001-9938-2691
Chiara BraconiSchool of Cancer Sciences, University of Glasgow , Glasgow, UK.ORCID 0000-0003-4835-1259
Jim C NormanCancer Research UK Scotland Institute , Glasgow, UK.ORCID 0000-0002-0098-3014

Funding

Breast Cancer Now 2018NovPR1268Cancer Research UK A18277Cancer Research UK Glasgow Centre C596/A18076Cancer Research UK Scotland Institute A31287Cancer Research UK Scotland Institute C596/A17196Medical Research Council MR/P01058×/1
6 · The paper itself

Abstract

The potential for using therapeutic antisense oligonucleotides (ASOs) has been hampered by a lack of understanding of how they enter cells and subsequently access their targets. Endocytosis contributes to ASO uptake, but the machinery mediating subsequent ASO trafficking to permit suppression of their target mRNAs has not been described. Here, we show that direct ASO engagement with a scavenger receptor (CD44) activates the ERK-RSK axis to promote serine phosphorylation of a receptor tyrosine kinase (EPHA2). Serine phosphorylation of EPHA2 permits endocytosis, trafficking, and accumulation of ASOs in nuclear-captured endosomes. These endosomes are then subject to lipid peroxidation and become leaky, allowing ASOs to escape and effectively suppress target mRNA expression. Inhibition of stress granule-mediated repair of these leaky endosomes further enhances ASO effectiveness. These data identify an endocytic route to the nucleus which may be exploited to maximize the effectiveness of ASO-mediated therapies.

Indexed as

EndosomesHyaluronan ReceptorsOligonucleotides, AntisenseReceptor, EphA2AnimalsEndocytosisHumansPhosphorylationProtein TransportCD44 protein, humanEPHA2 protein, humanHyaluronan ReceptorsOligonucleotides, AntisenseReceptor, EphA2

Identifiers

PMID42578958
PMCPMC13521514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.